{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:01:26Z","timestamp":1780038086714,"version":"3.53.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>\n                    <jats:italic>Mycobacterium avium<\/jats:italic>\n                    complex (MAC) is the most common non-tuberculous mycobacteria (NTM) and most frequent causative pathogen of NTM pulmonary infections. MAC is often associated with comorbidities, chronic infections, and high mortality rates. New treatment options are needed to increase treatment efficacy and tolerance. Omadacycline is a semisynthetic tetracycline-class drug with broad-spectrum activity, including against MAC\n                    <jats:italic>in vitro<\/jats:italic>\n                    . In an aerosol infection model of MAC pulmonary disease, we evaluated 9 treatment regimens that included omadacycline (OMC) alone or in dual, triple, or quadruple combinations with existing antibiotics: rifampin (RIF), clofazimine (CFZ), ethambutol (EMB), and clarithromycin (CLR). Treatment efficacy was assessed based on reduction of bacterial load in the lung and spleen over 4 months. OMC alone and OMC-RIF-EMB groups demonstrated efficacy starting at 2 months of treatment with a final reduction in bacterial burden in the lung of ~1 log\n                    <jats:sub>10<\/jats:sub>\n                    and &amp;gt;4 log\n                    <jats:sub>10<\/jats:sub>\n                    , respectively, compared with untreated mice. Omadacycline was as efficacious as rifampin in the standard-of-care regimen (CLR-RIF-EMB) over the first 3 months. The most potent combination tested in this study was OMC-CLR-CFZ, with a &amp;gt;5 log\n                    <jats:sub>10<\/jats:sub>\n                    reduction of bacterial burden in the lung. This is the first study demonstrating omadacycline efficacy against\n                    <jats:italic>M. avium<\/jats:italic>\n                    in mice alone and as part of a combination regimen. These data suggest that further evaluation of omadacycline for the treatment of MAC-PD is warranted.\n                  <\/jats:p>","DOI":"10.3389\/fmicb.2026.1821617","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:01:54Z","timestamp":1780034514000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of drug regimens containing omadacycline in a murine model of Mycobacterium avium chronic lung infection"],"prefix":"10.3389","volume":"17","author":[{"given":"Jean-Philippe","family":"Lanoix","sequence":"first","affiliation":[{"name":"AGIR EA4294, Universit\u00e9 de Picardie Jules Verne","place":["Amiens, France"]},{"name":"Infectious Diseases Department, Amiens-Picardie University Hospital","place":["Amiens, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Froment","sequence":"additional","affiliation":[{"name":"AGIR EA4294, Universit\u00e9 de Picardie Jules Verne","place":["Amiens, France"]},{"name":"Infectious Diseases Department, Amiens-Picardie University Hospital","place":["Amiens, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Delomez","sequence":"additional","affiliation":[{"name":"AGIR EA4294, Universit\u00e9 de Picardie Jules Verne","place":["Amiens, France"]},{"name":"Pneumology Department, Amiens-Picardie University Hospital","place":["Amiens, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica V.","family":"Pierce","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc.","place":["King of Prussia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa W.","family":"Serio","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc.","place":["King of Prussia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Choquet","sequence":"additional","affiliation":[{"name":"AGIR EA4294, Universit\u00e9 de Picardie Jules Verne","place":["Amiens, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Perret","sequence":"additional","affiliation":[{"name":"AGIR EA4294, Universit\u00e9 de Picardie Jules Verne","place":["Amiens, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Peltier","sequence":"additional","affiliation":[{"name":"AGIR EA4294, Universit\u00e9 de Picardie Jules Verne","place":["Amiens, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Joseph","sequence":"additional","affiliation":[{"name":"AGIR EA4294, Universit\u00e9 de Picardie Jules Verne","place":["Amiens, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Chatelain","sequence":"additional","affiliation":[{"name":"Pathology Department, Amiens-Picardie University Hospital","place":["Amiens, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Andr\u00e9jak","sequence":"additional","affiliation":[{"name":"AGIR EA4294, Universit\u00e9 de Picardie Jules Verne","place":["Amiens, France"]},{"name":"Pneumology Department, Amiens-Picardie University Hospital","place":["Amiens, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1128\/AAC.00830-09","article-title":"Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis","volume":"53","author":"Almeida","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1128\/AAC.04841-14","article-title":"Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations","volume":"59","author":"Andr\u00e9jak","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e01947","DOI":"10.1128\/AAC.01947-20","article-title":"In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/jac\/dkac356","article-title":"Investigating the immunomodulatory activities of omadacycline","volume":"78","author":"Bryant","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.7326\/0003-4819-121-12-199412150-00001","article-title":"Clarithromycin therapy for bacteremic Mycobacterium avium complex disease","volume":"121","author":"Chaisson","year":"1994","journal-title":"Ann. Intern. Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/jac\/dkac068","article-title":"Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses","volume":"77","author":"Chapagain","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1093\/infdis\/jiaa354","volume":"222","author":"Daley","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1128\/AAC.36.9.2066","article-title":"Bioavailability of rifampin in experimental murine tuberculosis","volume":"36","author":"Dickinson","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0046925","DOI":"10.1128\/aac.00469-25","article-title":"Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia","volume":"69","author":"Gomi","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.chest.2020.10.031","article-title":"Managing Mycobacterium avium complex lung disease with a little help from my friend","volume":"159","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.200407-863OC","article-title":"Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease","volume":"172","author":"Griffith","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1128\/AAC.36.3.548","article-title":"Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice","volume":"36","author":"Grosset","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1164\/rccm.201304-0753OC","article-title":"Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice","volume":"188","author":"Grosset","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4046\/trd.2018.0060","article-title":"Treatment of Mycobacterium avium complex pulmonary disease","volume":"82","author":"Kwon","year":"2019","journal-title":"Tuberc. Respir. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e02349","DOI":"10.1128\/AAC.02349-19","article-title":"Synergistic activity of clofazimine and clarithromycin in an aerosol mouse model of Mycobacterium avium infection","volume":"64","author":"Lanoix","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1242\/dmm.019513","article-title":"Heterogeneous disease progression and treatment response in a C3HeB\/FeJ mouse model of tuberculosis","volume":"8","author":"Lanoix","year":"2015","journal-title":"Dis. Model. Mech."},{"key":"B18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40261-022-01119-9","article-title":"Omadacycline oral dosing and pharmacokinetics in community-acquired Bacterial pneumonia and acute bacterial skin and skin structure infection","volume":"42","author":"Leviton","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"dkaf413","DOI":"10.1093\/jac\/dkaf413","article-title":"Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies","volume":"81","author":"Mudde","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0170421","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","unstructured":"King of Prussia, PA\n          Paratek Pharmaceuticals, Inc\n          I. NUZYRA (2021) [package insert].\n          \n          2021"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0066522","DOI":"10.1128\/msphere.00665-22","article-title":"Efficacy of omadacycline-containing regimen in a mouse model of pulmonary Mycobacteroides abscessus disease","volume":"8","author":"Rimal","year":"2023","journal-title":"mSphere"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0067124","DOI":"10.1128\/msphere.00671-24","article-title":"Immunomodulatory activity of omadacycline in vitro and in a murine model of acute lung injury","volume":"9","author":"Sanders","year":"2024","journal-title":"mSphere"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0087423","DOI":"10.1128\/aac.00874-23","article-title":"The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease","volume":"67","author":"Schildkraut","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"102269","DOI":"10.1016\/j.tube.2022.102269","article-title":"Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"137","author":"Shankar","year":"2022","journal-title":"Tuberculosis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1093\/cid\/ciaa1361","article-title":"Management of drug toxicity in Mycobacterium avium complex pulmonary disease: an expert panel survey","volume":"73","author":"van Ingen","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2302210","DOI":"10.1183\/13993003.02210-2023","article-title":"Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint","volume":"63","author":"van Ingen","year":"2024","journal-title":"Eur. Respir. J."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag062","article-title":"Omadacycline monotherapy in nontuberculous mycobacterial pulmonary disease caused by Mycobacterium abscessus?: Results from a phase 2, double-blind, randomized, placebo-controlled study","author":"Winthrop","year":"2026","journal-title":"Clin Infect Dis."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1821617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:01:55Z","timestamp":1780034515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1821617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":29,"alternative-id":["10.3389\/fmicb.2026.1821617"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1821617","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1821617"}}